DLK2 inhibitors constitute a class of chemical compounds that have garnered attention within the realm of molecular biology and pharmacology due to their potential significance in regulating cellular processes. DLK2, or Dual Leucine Zipper Kinase 2, is a protein kinase with multifaceted functions in cellular signaling and pathways. One of its primary roles is to phosphorylate specific substrates, thereby modulating various intracellular processes. DLK2 inhibitors are designed to interact with the active site or binding pocket of DLK2, effectively hindering its catalytic activity and altering its ability to phosphorylate target proteins. This inhibition has far-reaching implications for intracellular signaling cascades and cellular response to external stimuli.
Structurally, DLK2 inhibitors are tailored to bind to DLK2's active site with a high degree of specificity, ensuring that they exert their inhibitory effects selectively on this kinase. By perturbing DLK2's enzymatic function, these inhibitors disrupt downstream signaling pathways that depend on DLK2-mediated phosphorylation events. Consequently, they may influence cellular processes like cell growth, differentiation, and stress responses. The study of DLK2 inhibitors is of substantial interest to researchers, as it provides a deeper understanding of the regulatory mechanisms governing vital cellular functions. This knowledge serves to advance our comprehension of basic cell biology, and while it has potential applications in diverse research domains, further investigation is necessary to elucidate the full scope of their utility.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Through its impact on Wnt signaling and GSK-3 inhibition, it might indirectly affect DLK2 expression. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Inhibits the Hedgehog signaling pathway, which might have a downstream effect on DLK2 expression. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
A gamma-secretase inhibitor, potentially affecting Notch signaling and indirectly DLK2 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAPK, potentially impacting signaling pathways that regulate DLK2 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR pathway, which could affect protein synthesis and potentially DLK2 expression. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
Wnt pathway inhibitor, potentially impacting signaling pathways that regulate DLK2 expression. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
TGF-beta receptor kinase inhibitor, could influence DLK2 expression through TGF-beta signaling. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor, could alter gene expression patterns including DLK2 expression. | ||||||